PhageLab has a total of 21 patents globally, out of which 8 have been granted. Of these 21 patents, more than 71% patents are active. The United States of America, Chile and Europe (EPO) is where PhageLab has filed the maximum number of patents, followed by Brazil. Parallelly, United States of America seems to be the main focused R&D center of PhageLab and also Chile is the origin country of PhageLab.
Phagelab, founded in 2010, is a biotechnology company based in Chile that develops bacteriophage-based solutions to reduce bacterial infections in animal farming and food production. In 2025, the company received a WIPO Global Award for its work in applying phage technology to agriculture.
Phagelab’s patent filings cover areas such as Salmonella control using phage cocktails, AI-assisted development of antibacterial therapies, veterinary treatments and disinfection, prediction tools for phage-bacteria matching, and food safety applications. Do read about some of the most popular patents of PhageLab which have been covered by us in this article and also you can find PhageLab patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over PhageLab patent portfolio.
How many patents does PhageLab have?
PhageLab has a total of 21 patents globally. These patents belong to 7 unique patent families. Out of 21 patents, 15 patents are active.
How Many Patents did PhageLab File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | PhageLab Applications Filed | PhageLab Patents Granted |
| 2024 | – | 1 |
| 2023 | 4 | 7 |
| 2022 | 10 | – |
| 2021 | 7 | – |
How many PhageLab patents are Alive/Dead?
Worldwide Patents
How Many Patents did PhageLab File in Different Countries?
Countries in which PhageLab Filed Patents
| Country | Patents |
| United States Of America | 3 |
| Chile | 3 |
| Europe (EPO) | 3 |
| Brazil | 2 |
| Argentina | 1 |
| Austria | 1 |
| Germany | 1 |
| Poland | 1 |
What Technologies are Covered by PhageLab?
1. Phage Therapy for Salmonella Control (2 Families)
This is the most prominent area in the portfolio. The patents focus on bacteriophage cocktails specifically targeting Salmonella spp., with broad-spectrum lytic activity. These formulations are used for preventing and treating infections in livestock, particularly poultry, as well as for surface and equipment disinfection in food processing environments. The technologies support antibiotic-free pathogen control, aligning with clean-label and biosecurity standards in the food and agriculture industries.
2. AI-Driven Antibacterial Therapy (2 Families)
These patents combine artificial intelligence with bacteriophage therapy, leveraging machine learning to design effective phage cocktails. The systems can predict which phages will be most effective against specific bacterial strains. This area represents an emerging fusion of synthetic biology and AI, aiming to solve challenges posed by antibiotic resistance with precision-designed biological alternatives.
3. Veterinary Therapeutics and Disinfection (1 Family)
This category includes formulations developed for veterinary use especially in livestock and as environmental sanitizers. The technology uses phages that target zoonotic pathogens like Salmonella, designed for oral delivery to animals or for application on surfaces in animal housing or food processing setups. This dual-purpose innovation enhances both animal health and hygiene.
4. AI-Driven Phage Therapy Prediction (1 Family)
Here, the focus is on computational models that use genomic and proteomic data to predict bacteriophage-host interactions. These patents detail machine learning algorithms that forecast whether a specific phage can lyse a target bacterium, using protein-protein interaction matrices and in vitro data. It enables smarter, faster phage selection with potential applications in both research and clinical phage therapy.
5. Food Safety and Biocontrol Agents (1 Family)
This area covers the use of bacteriophage formulations for reducing foodborne pathogens during production and storage. The technology emphasizes natural, clean-label microbial control in foods like meat products, addressing Pseudomonas lundensis and similar spoilage bacteria. These biocontrol agents help extend shelf life and meet consumer demand for chemical-free preservation methods.
Where are Research Centers of PhageLab Patents Located?
What Percentage of PhageLab US Patent Applications were Granted?
PhageLab (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 100.0%.
Below are the key stats of PhageLab patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for PhageLab?
| Law Firm | Total Applications | Success Rate |
| Lucas & Mercanti Llp | 3 | 100.00% |
List of PhageLab Patents
| PhageLab Patents | Title |
| US20240245065A1 | Bacteriophages And Compositions Thereof For Controlling The Growth Of Pseudomonas Lundensis In Meat Products |
| US20240087684A1 | Methods And Systems For Designing Phage Cocktails |
| US11826391B2 | Antibacterial Formulation Comprising A Mixture Of Bacteriophages; Use And Method For Preventing Or Treating Diseases Caused By Salmonella Spp. In Farm Animals By Oral Administration Of The Formulation |
| EP4313092A4 | Methods And Systems For Designing Phage Cocktails |
| EP4344399A1 | Bacteriophages And Compositions Thereof For Controlling The Growth Of Pseudomonas Lundensis In Meat Products |
| EP4111865B1 | Antibacterial Formulation Of A Mixture Of Bacteriophages For Use In Preventing Or Treating Diseases Caused By Salmonella Spp. |
| WO2024231715A1 | Systems And Methods For Predicting Bacteriophage Host Range |
| BR112022022363A2 | Compositions For The Treatment Of E. Coli And Salmonella |
| BR112022006931B1 | Antibacterial Formulation Comprising A Mixture Of Bacteriophages; Use And Method Of Prevention Or Treatment Of Diseases Caused By Salmonella Spp. In Farm Animals By Oral Administration Of The Formulation |
| AR128217A1 | Compositions For The Treatment Of E. Coli And Salmonella |
| CL202301401A1 | Methods And Systems For The Design Of Phage Cocktails |
| CL67265B | Compositions For The Treatment Of E. Coli And Salmonella. |
| PL4111865T3 | Antibacterial Formulation Of A Mixture Of Bacteriophages For Use In Preventing Or Treating Diseases Caused By Salmonella Spp. |
| CL67035B | Antibacterial Formulation Composed Of A Mixture Of Bacteriophages; Use And Method To Prevent Or Treat Diseases Caused By Salmonella Spp. In Farmed Animals Through Oral Administration Of The Formulation |
| DE602021002205T2 | Antibacterial Formulation Of A Mixture Of Bacteriophages For The Prevention Or Treatment Of Diseases Caused By Salmonella Spp. Caused |
| WO2024042387A1 | Bacteriophage Cocktail With Broad-Spectrum Lytic Activity Against Salmonella Serovars |
| WO2024033686A1 | Bacteriophages And Compositions Thereof For Controlling The Growth Of Pseudomonas Lundensis In Meat Products |
| WO2023242621A1 | Methods And Systems For Designing Phage Cocktails |
| WO2023152549A1 | Compositions For The Treatment Of E. Coli And Salmonella |
| WO2022241579A1 | Antibacterial Formulation Made Of A Mixture Of Bacteriophages, Use Thereof, And Method For Preventing Or Treating Diseases Caused By Salmonella Spp. In Breeding Animals, By Orally Administering The Formulation |
| AT1563829T | Antibacterial formulation containing a mixture of bacteriophages for the prevention or treatment of diseases caused by Salmonella spp. |
EXCLUSIVE INSIGHTS COMING SOON!
Curious about PhageLab innovations? Fill out the form below to request a detailed patent report on this technology!
